Hoʻonui ʻo Novel Promoter Strategy i ka palekana a me ka maikaʻi o ka CAR-T Therapy i ka Acute B Cell Leukemia

Beijing, Kina - Iulai 23, 2024- Ma kahi hoʻomohala honua, ʻo ka Halemai ʻo Lu Daopei, me ka hui pū ʻana me Hebei Senlang Biotechnology, ua wehe i nā hopena hoʻohiki mai kā lākou noiʻi hou loa e pili ana i ka chimeric antigen receptor T (CAR-T) cell therapy. ʻO kēia haʻawina, e kālele ana i ka pono a me ka palekana o nā pūnaewele CAR-T i hana ʻia me nā mea hoʻolaha like ʻole, e hōʻailona ana i kahi holomua nui i ka mālama ʻana i ka maʻi leukemia B cell (B-ALL).

ʻO ka haʻawina, i kapa ʻia ʻo "Promoter Usage Regulating the Surface Density of CAR Molecules May Modulate the Kinetics of CAR-T Cells In Vivo," e ʻimi ana pehea e hiki ai i ke koho o ka mea hoʻolaha ke hoʻoikaika i ka hana o nā cell CAR-T. ʻO nā mea noiʻi ʻo Jin-Yuan Ho, Lin Wang, Ying Liu, Min Ba, Junfang Yang, Xian Zhang, Dandan Chen, Peihua Lu, a me Jianqiang Li mai Hebei Senlang Biotechnology a me Lu Daopei Hospital i alakaʻi i kēia noiʻi.

Hōʻike kā lākou mau ʻike i ka hoʻohana ʻana i ka MND (myeloproliferative sarcoma virus MPSV enhancer, ka hoʻopau ʻana i ka ʻāina NCR maikaʻi ʻole, d1587rev primer binding site replacement) mea hoʻolaha i nā pūnaewele CAR-T e alakaʻi i ka haʻahaʻa haʻahaʻa o nā molekala CAR, a laila e hōʻemi i ka hana cytokine. He mea koʻikoʻi kēia no ka mea kōkua ia i ka hoʻēmi ʻana i nā hopena ʻaoʻao koʻikoʻi e pili pinepine ana me ka therapy CAR-T, e like me ka cytokine release syndrome (CRS) a me CAR-T cell-related encephalopathy syndrome (CRES).

ʻO ka hoʻokolohua lapaʻau, i hoʻopaʻa inoa ʻia ma lalo o ClinicalTrials.gov identifier NCT03840317, ua hoʻokomo ʻia nā maʻi 14 i māhele ʻia i ʻelua cohorts: hoʻokahi e loaʻa ana i nā pūnaewele CAR-T hoʻokele MND a ʻo nā mea ʻē aʻe e loaʻa ana i nā pūnaewele CAR-T hoʻolaha EF1A. ʻO ka mea kupaianaha, ua loaʻa i nā maʻi āpau i mālama ʻia me ka MND-driven cell CAR-T i ke kala piha ʻana, me ka hapa nui o lākou e hōʻike ana i ke kūlana liʻiliʻi liʻiliʻi ma hope o ka mahina mua. Ua hōʻike pū ʻia ka haʻawina he haʻahaʻa haʻahaʻa o ka CRS koʻikoʻi a me CRES i nā maʻi i mālama ʻia me nā pūnaewele CAR-T hoʻokele MND i hoʻohālikelike ʻia me nā mea i mālama ʻia me nā pūnaewele EF1A.

Ua hōʻike ʻo Kauka Peihua Lu mai ka Halemai ʻo Lu Daopei i ka manaʻo maikaʻi e pili ana i ka hiki o kēia ala hou, me ka ʻōlelo ʻana, "ʻO kā mākou hui pū ʻana me Hebei Senlang Biotechnology ua hāʻawi mai i nā ʻike koʻikoʻi i ka hoʻomaikaʻi ʻana i ka cell therapy CAR-T. ʻO ka hoʻomaʻamaʻa ʻana me ka mālama ʻana i kona pono he hana koʻikoʻi kēia i ka hana ʻana i ka lāʻau lapaʻau CAR-T i ʻoi aku ka maʻalahi o nā maʻi.

Ua kākoʻo ʻia ke aʻo ʻana e nā haʻawina mai ka Natural Science Foundation o Hebei Province a me ke Keʻena ʻepekema a me ʻenehana o Hebei Province. Hōʻike ia i ke koʻikoʻi o ka koho hoʻolaha i ka hoʻomohala ʻana i nā lāʻau lapaʻau CAR-T a wehe i nā ala hou no ka mālama ʻana i ka maʻi maʻi palekana a ʻoi aku ka maikaʻi.